Analysts Impressed As Novo Nordisk’s PIONEER 6 Trial Confirms Safety Profile Of Oral Semaglutide

Oral semaglutide hit its main endpoint by demonstrating cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in the PIONEER 6 trial.

Heart
Trial is part of Novo Nordisk's PIONEER clinical development program • Source: Shutterstock

Novo Nordisk AS’s investigational oral version of its GLP-1 agonist semaglutide is safe in patients with type 2 diabetes at high cardiovascular risk, according to full results from the PIONEER 6 study released at the American Diabetes Association (ADA) on 11 June, which showed a non-significant 21% reduction in major adverse cardiac events (MACE).

Full results of PIONEER 6, topline data from which was released last November, showed the trial met the primary objective...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category